Roche exec moves on to CEO job at Enlight; FDA approves Merck melanoma drug;

 @FierceBiotech:  Intercell shares nosedive as investigators slam brakes on patient recruitment. Story | Follow @FierceBiotech

 @JohnCFierce: So Inspiration, now in Ireland scouting plants, recently raised its financing to $247 million. News | Follow @JohnCFierce

> After 18 years at Roche, former global head of emerging science and technology Michelle Browner is moving on to become CEO at Boston-based Enlight Biosciences, reports Xconomy. Article

> The FDA has granted Merck approval of Sylatron. The drug is given to patients with node-positive melanoma after the affected area has been removed. News

> Vernalis has regained rights to early-stage Parkinson's drug vipadenant from Biogen Idec. Report

Pharma News

@FiercePharma: J&J agrees to pay $70M in corruption probe. Story | Follow @FiercePharma

> Study: Forest Labs drug no help in mild Alzheimer's. Article

> Endo CEO: More buyouts, but smaller. Report

> Can Indian pharma fully exploit the patent cliff? Report

Biotech Research News

> WHO warns of impending drug-resistance crisis. Article 

> Dogs help humans narrow down lymphoma genes. Report 

> Alzheimer's mice at center of academic vs. property rights. Story 

> Two genes found for caffeine cravings. Item 

> Visionary scientists grow retina from stem cells. Report 

Manufacturing News

> Gartner taps TraceLink for supply chain kudos. Article 

> CMO Lonza builds in UK for bio business. Item 

> Serialization mandates highlight need for expertise. News

> GSK moves bioprocessing to UK from India. Story 

> TraceLink wins supply chain kudos. News 

And Finally... If your baby won't sleep through the night, don't blame the inconvenience on genes. That's the conclusion made by researchers in Italy who found that parents are largely in control of their toddler's sleep habits, reports the Los Angeles Times. Report

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.